NKGNNKGen Biotech, Inc.

Nasdaq nkgenbiotech.com


$ 1.23 $ -0.07 (-5.38 %)    

Thursday, 27-Jun-2024 11:26:42 EDT
QQQ $ 481.39 $ 1.41 (0.29 %)
DIA $ 390.26 $ -0.98 (-0.25 %)
SPY $ 545.35 $ -0.14 (-0.03 %)
TLT $ 93.48 $ 0.05 (0.05 %)
GLD $ 214.86 $ 0.15 (0.07 %)
$ 1.3
$ 1.34
$ 1.21 x 100
$ 0.00 x 0
$ 1.23 - $ 1.34
$ 0.78 - $ 12.88
134,681
na
28.52M
$ -0.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-20-2024 03-31-2024 10-Q
2 04-16-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-nkgen-biotech-stock-is-moving-higher-monday

NKGen Biotech shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 tri...

Core News & Articles
Market-Moving News for May 20th
05/20/2024 12:37:59

PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation NKGN: 81% | NK...

Core News & Articles
Market-Moving News for April 29th
04/29/2024 12:46:23

TSLA: 14% | Tesla shares are trading higher on reports the company will partner with Baidu for mapping and navigation for Full ...

 nkgen-biotech-announces-fda-clearance-of-ind-application-for-snk01-nk-cell-therapy-in-parkinsons-disease

NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients...

 whats-going-on-with-nano-cap-nkgen-biotech-stock-on-monday

Latest on NKGen Biotech Inc (NASDAQ: NKGN) as shares surge 25.2% on high volume. Insights into NK cell therapy for neurodegener...